Literature DB >> 17921328

Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury.

Jingang Zheng1, Rubio Wang, Edward Zambraski, Dan Wu, Kenneth A Jacobson, Bruce T Liang.   

Abstract

Although adenosine exerts cardio-and vasculoprotective effects, the roles and signaling mechanisms of different adenosine receptors in mediating skeletal muscle protection are not well understood. We used a mouse hindlimb ischemia-reperfusion model to delineate the function of three adenosine receptor subtypes. Adenosine A(3) receptor-selective agonist 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide (Cl-IBMECA; 0.07 mg/kg ip) reduced skeletal muscle injury with a significant decrease in both Evans blue dye staining (5.4 +/- 2.6%, n = 8 mice vs. vehicle-treated 28 +/- 6%, n = 7 mice, P < 0.05) and serum creatine kinase level (1,840 +/- 910 U/l, n = 13 vs. vehicle-treated 12,600 +/- 3,300 U/l, n = 14, P < 0.05), an effect that was selectively blocked by an A(3) receptor antagonist 3-ethyl-5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1,4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS-1191; 0.05 mg/kg). The adenosine A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA; 0.05 mg/kg) also exerted a cytoprotective effect, which was selectively blocked by the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 0.2 mg/kg). The adenosine A(2A) receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS-21680; 0.07 mg/kg)-induced decrease in skeletal muscle injury was selectively blocked by the A(2A) antagonist 2-(2-furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e] [1,2,4]triazolo[1,5-C]pyrimidin-5-amine (SCH-442416; 0.017 mg/kg). The protection induced by the A(3) receptor was abrogated in phospholipase C-beta2/beta3 null mice, but the protection mediated by the A(1) or A(2A) receptor remained unaffected in these animals. The adenosine A(3) receptor is a novel cytoprotective receptor that signals selectively via phospholipase C-beta and represents a new target for ameliorating skeletal muscle injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921328      PMCID: PMC6309900          DOI: 10.1152/ajpheart.00819.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  31 in total

1.  Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor.

Authors:  Athena M Keene; Ramachandran Balasubramanian; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

2.  Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Dilip K Tosh; Moshe Chinn; Andrei A Ivanov; Athena M Klutz; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 3.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

4.  Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation.

Authors:  Liaman K Mamedova; Ruibo Wang; Pedro Besada; Bruce T Liang; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2008-08-30       Impact factor: 7.658

5.  Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.

Authors:  Artem Melman; Zhan-Guo Gao; Deepmala Kumar; Tina C Wan; Elizabeth Gizewski; John A Auchampach; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2008-04-04       Impact factor: 2.823

6.  Tissue-specific epigenetics in gene neighborhoods: myogenic transcription factor genes.

Authors:  Sruti Chandra; Jolyon Terragni; Guoqiang Zhang; Sriharsa Pradhan; Stephen Haushka; Douglas Johnston; Carl Baribault; Michelle Lacey; Melanie Ehrlich
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

Review 7.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Bruce T Liang; Kenneth A Jacobson
Journal:  Drug Discov Today       Date:  2011-10-19       Impact factor: 7.851

8.  Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Authors:  Zhoumou Chen; Kali Janes; Collin Chen; Tim Doyle; Leesa Bryant; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

Review 9.  G protein coupled receptors signaling pathways implicate in inflammatory and immune response of rheumatoid arthritis.

Authors:  Jinling Shu; Feng Zhang; Lingling Zhang; Wei Wei
Journal:  Inflamm Res       Date:  2016-11-23       Impact factor: 4.575

10.  Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor.

Authors:  Yoonkyung Kim; Sonia de Castro; Zhan-Guo Gao; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.